3 completed, 2 recruiting. 3 Phase 4, 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Cytochrome P-450 CYP3A: new trials by email Literature Review of Cytochrome P-450 CYP3A trials Research Report on Cytochrome P-450 CYP3A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam) - Solid Tumours | Phase 1 | Completed | AstraZeneca | 33 | 2017-12-01 | 2019-03-25 |
| Influence of Diabetes on Tramadol Pharmacokinetics Single oral dose of 100 mg racemic tramadol, CYP2D6 phenotype, CYP3A phenotype - Neuropathic Pain, Type 1 Diabetes Mellitus | Phase 4 | Completed | Universidade Estadual Paulista Júlio de Mesquita Filho | 30 | 2008-06-01 | 2014-09-23 |
| A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas ixabepilone, pharmacological study, Anticonvulsant - Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 57 | 2002-10-01 | 2017-10-18 |
Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Leukemia, Myeloid, Acute (1) · Neuralgia (1) · Thyroid Neoplasms (1)
Rigel Pharmaceuticals (2) · AstraZeneca (1) · National Cancer Institute (NCI) (1) · Universidade Estadual Paulista Júlio de Mesquita Filho (1)
United States (3) · Brazil (1) · Spain (1)
David Peereboom, MD (1) · Ding Wang, MD (1) · Lone Ottesen, MD (1) · Natalia V de Moraes, PhD (1)
PMID 22173007, PMID 24717054, PMID 37368100, PMID 37394627
U01CA062475 (1)